 |
|
Jörn Aldag
Chief Executive Officer
Mr. Aldag joined uniQure’s predecessor company AMT in October 2009. He has led uniQure’s corporate development including the build-up of its gene therapy pipeline, the marketing authorization process at EMA for Glybera, and several dilutive and non-dilutive financing transactions. Before joining uniQure he was instrumental in building Evotec AG (FSE: EVT), from 1997 to 2000 as CFO and from 2001 to 2009 as President and CEO. EVT designed and implemented a cutting edge small molecule technology platform, became a leader in drug discovery services and developed a promising CNS pipeline. Prior to Evotec, Jörn Aldag served in various financial management positions at MAN AG, and as Business Director at Treuhandanstalt, the agency responsible for privatizing the East German economy after the German reunification. Jörn Aldag is Chairman of Molecular Partners AG, Zurich, Switzerland, and holds business degrees from the Harvard Business School and the European Business School.
|
 |
|
Piers Morgan
VP, Chief Financial Officer
Mr. Morgan joined uniQure’s predecessor company AMT in December 2009 as Chief Financial Officer. He has over ten years experience as CFO with biotechnology companies, including Phytopharm plc, BioAlliance Pharma SA, and Arrow Therapeutics Ltd. Prior to this period, he gained ten years experience in investment banking, working in Mergers & Acquisitions, and Equity Capital Markets with Close Brothers and Ernst & Young Corporate Finance. He qualified as a Chartered Accountant in London with PricewaterhouseCoopers.
|
 |
|
Hans Christian Rohde (M.Sc., MBA)
Chief Commercial Officer
Chief Commercial Officer Hans Christian Rohde (M.Sc., MBA) has almost 25 years experience in commercial roles at leading biotechnology and pharmaceutical companies. From 2007 until 2012 he was Chief Commercial Officer at Basilea Pharmaceutica, and member of the company’s executive management committee with responsibility for global commercial operations, marketing, supply chain, medical affairs, pricing and market access.Prior to Basilea Pharmaceutica, Mr. Rohde was Corporate Vice President, Head of Global Therapeutic Areas Reproductive Health and Endocrinology at Merck-Serono from 2003 until 2007. Before this he was responsible for international marketing and global market development at Biogen Idec. From 1992 until 2000, Mr Rohde held positions of increasing commercial responsibility at Novo Nordisk. Mr. Rohde started his career at Laboratoires Syntex.
|
 |
|
Harald Petry PhD
VP, Research & Development
Dr. Petry joined uniQure’s predecessor company AMT in May 2007 as Director of Research and Development. He has worked in the area of gene therapy for more than 15 years and has extensive experience in pharmaceutical research. After his PhD, he built up a career in academic research and subsequently in the international biopharmaceutical industry. For the last 10 years, in addition to uniQure, he has worked at Jenapharm GmbH (Germany), and Berlex Biosciences (US) in different functions with increasing managerial and leadership responsibility. |
 |
|
Hans Preusting PhD, MBA
VP, Business Development
Dr. Preusting joined uniQure’s predecessor company AMT in August 2006 and is responsible for Business Development. He holds a PhD in Biochemistry and an MBA from Rotterdam School of Management. He has 20 years of experience in product development and manufacturing using fermentation and cell culture techniques. Prior to uniQure, he was at Solvay Pharmaceuticals, DSM and Gist-brocades. Hans Preusting holds two patents and has published over 20 scientific articles.
|
